REPERTOIRE GENESIS INCORPORATION;HYOGO COLLEGE OF MEDICINE
发明人:
MATSUMOTO SEIJI,SUZUKI RYUJI
申请号：
CA3057041
公开号：
CA3057041A1
申请日:
2018.03.14
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention provides a technique for predicting a responder prior to beginning cancer immunotherapy. The present invention provides a method for using the T cell receptor (TCR) diversity of a subject as an indicator of the responsiveness of the subject to cancer immunotherapy. The present invention also provides a composition including an immune checkpoint inhibitor, wherein the composition is for treating cancer in a subject having high TCR diversity of the T cells. The present invention also pertains to a companion drug in which such TCR diversity is used.
